Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine--a comparison of 1- and 3-month immunization schedules

J Infect Dis. 1998 Jan;177(1):221-3. doi: 10.1086/517358.

Abstract

Live attenuated SA14-14-2 Japanese encephalitis (JE) vaccine has been safe and effective in >100 million immunized children, but its current administration schedule of two doses given a year apart does not lend itself to inclusion in established Expanded Program of Immunization (EPI) schedules of childhood immunization. Immune responses to immunization at shorter intervals were compared in middle-school-aged children immunized with two doses separated by 1 month (n = 116) or 2.5 months (n = 115). Two vaccine lots were compared. Seroconversion to the vaccine was observed in 100% of vaccinees immunized in the 1-month schedule and in 94% (lot 2) and 100% (lot 1) of vaccinees immunized in the 2.5-month schedule. Geometric mean titers were almost 2-fold higher with the longer schedule. The routine administration of JE SA14-14-2 vaccine to infants in an EPI schedule should be possible using either interval.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Animals
  • Antibodies, Viral / analysis*
  • Antibodies, Viral / immunology
  • Cells, Cultured
  • Child
  • Chlorocebus aethiops
  • Encephalitis, Japanese / immunology
  • Encephalitis, Japanese / prevention & control*
  • Humans
  • Immunization Schedule*
  • Neutralization Tests
  • Vaccines, Attenuated / administration & dosage*
  • Vaccines, Attenuated / immunology
  • Vero Cells
  • Viral Vaccines / administration & dosage*
  • Viral Vaccines / immunology

Substances

  • Antibodies, Viral
  • Vaccines, Attenuated
  • Viral Vaccines